Profile data is unavailable for this security.
About the company
NGL Fine-Chem Limited is an India-based manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. The Company caters to various global companies to custom manufacture pharmaceuticals. Its products include APIs Animal Health, APIs Human Health, Intermediates and Specialty Chemicals and Finished Dosage Form. The APIs Animal Health products include Homidium Chloride, Nitroxynil, Clorsulon, Parvaquone, Buparvaquone, Isometamidium Chloride Hydrochloride, Toldimfos Sodium, Butaphosphan, Imidocarb Dipropionate, Triclabendazole, Rafoxanide, Diminazene Aceturate, S-Methoprene, Carprofen, Flunixin Meglumine, and Imidocarb Dipropionate, among others. The APIs Human Health products include Nitazoxanide and Atovaquone. The Intermediates and Specialty Chemicals product includes 1,4,7-Trimethyl-1,4,7-Triazacylononane and N-Ethyl Glucamine. The Finished Dosage Form products include Diminazene Aceturate Granules and Homidium Chloride Tablets.
- Revenue in INR (TTM)2.82bn
- Net income in INR-817.29m
- Incorporated1981
- Employees329.00
- LocationNgl Fine Chem LtdMetalage Indust CompoundSubhash Road, Jogeshwari EastMUMBAI 400057IndiaIND
- Phone+91 2 240842222
- Fax+91 2 240539900
- Websitehttp://www.nglfinechem.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Windlas Biotech Ltd | 4.95bn | 459.70m | 5.08bn | 962.00 | 11.40 | -- | 8.82 | 1.03 | 21.13 | 21.13 | 227.25 | -- | -- | -- | -- | 5,140,343.00 | -- | -- | -- | -- | 36.09 | -- | 9.30 | -- | -- | 50.42 | -- | -- | 8.96 | -- | 140.58 | -- | -- | -- |
| Syncom Formulations India Ltd | 2.22bn | 163.62m | 5.50bn | -- | 28.73 | -- | 26.51 | 2.48 | 0.2037 | 0.2037 | 2.65 | -- | -- | -- | -- | -- | -- | 7.84 | -- | 10.43 | 36.15 | 31.24 | 7.39 | 8.17 | -- | 4.10 | -- | -- | -10.27 | 3.51 | -32.16 | 13.19 | 7.58 | 8.45 |
| SMS Pharmaceuticals Ltd | 4.34bn | -41.61m | 5.58bn | 1.03k | -- | -- | 14.87 | 1.29 | -0.4871 | -0.4871 | 51.05 | -- | -- | -- | -- | 4,205,091.00 | -- | 7.71 | -- | 10.22 | 22.94 | 34.08 | 1.25 | 10.04 | -- | -0.227 | -- | 5.01 | -7.69 | 3.08 | -0.491 | 16.91 | 3.26 | 8.45 |
| Beta Drugs Ltd | -100.00bn | -100.00bn | 5.95bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 57.91 | -- | 356.78 | -- | -- | -- |
| Vimta Labs Ltd | 3.10bn | 473.23m | 6.51bn | 1.27k | 14.03 | -- | 8.50 | 2.10 | 20.99 | 20.99 | 137.66 | -- | -- | -- | -- | 2,438,790.00 | -- | 8.88 | -- | 11.18 | 76.75 | 71.34 | 15.24 | 10.45 | -- | 21.68 | -- | 15.89 | 32.09 | 12.58 | 93.09 | 31.30 | -0.5906 | -- |
| Panacea Biotec Ltd | 4.72bn | 12.17bn | 6.76bn | 1.06k | 0.556 | -- | 0.5504 | 1.43 | 198.47 | 198.47 | 77.11 | -- | -- | -- | -- | 4,458,904.00 | -- | 9.69 | -- | 17.46 | 43.98 | 55.39 | 257.85 | 24.67 | -- | -2.27 | -- | 0.00 | 5.83 | 3.46 | 837.06 | -- | -12.14 | -- |
| Lincoln Pharmaceuticals Ltd | 5.00bn | 713.61m | 6.83bn | 1.25k | 9.57 | -- | 8.53 | 1.37 | 35.62 | 35.62 | 249.77 | -- | -- | -- | -- | -- | -- | 13.45 | -- | 17.08 | 52.37 | 50.55 | 14.26 | 13.25 | -- | 56.07 | -- | -- | 11.30 | 5.26 | 11.46 | 19.79 | 20.91 | 4.56 |
| Medico Remedies Ltd | -100.00bn | -100.00bn | 6.94bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.41 | -- | 7.20 | -- | 24.67 | -- | 2.43 | -- | -- | -- | -- | -1.12 | 17.33 | 88.68 | 24.60 | -4.35 | -- |
| Zota Health Care Ltd | 1.34bn | -41.49m | 7.40bn | 297.00 | -- | -- | 134.17 | 5.50 | -1.65 | -1.65 | 53.61 | -- | -- | -- | -- | 4,526,751.00 | -- | 5.37 | -- | 7.05 | 36.48 | 30.73 | -3.09 | 4.88 | -- | -1.62 | -- | 67.63 | 22.85 | 12.88 | 4,364.05 | 9.96 | 11.07 | 0.9805 |
| Jagsonpal Pharmaceuticals Ltd | 2.25bn | 204.13m | 7.69bn | -- | 37.70 | -- | 35.32 | 3.42 | 7.79 | 7.79 | 85.90 | -- | -- | -- | -- | -- | -- | 5.39 | -- | 6.85 | 60.36 | 58.22 | 9.08 | 4.60 | -- | 98.92 | -- | 38.85 | 15.77 | 8.44 | 10.54 | 9.71 | -28.93 | 109.13 |
| NGL Fine-Chem Ltd | 2.82bn | -817.29m | 7.77bn | 329.00 | -- | -- | -- | 2.75 | -132.29 | -132.29 | 457.23 | -- | -- | -- | -- | 8,580,666.00 | -- | 17.96 | -- | 24.18 | 13.77 | 48.76 | -28.95 | 14.83 | -- | -63.53 | -- | 2.93 | 23.08 | 24.42 | -12.03 | 27.37 | 22.93 | -- |
| Medicamen Biotech Ltd | 1.25bn | 137.00m | 7.83bn | 357.00 | 56.22 | -- | 39.21 | 6.27 | 11.01 | 11.01 | 100.53 | -- | -- | -- | -- | 3,500,164.00 | -- | 8.02 | -- | 11.97 | 51.22 | 33.66 | 10.97 | 10.62 | -- | 6.12 | -- | 9.01 | 2.42 | 6.96 | 22.82 | 23.62 | 29.99 | 0.00 |
| Bliss GVS Pharma Ltd | 7.34bn | 871.47m | 7.88bn | 750.00 | 9.22 | -- | 6.87 | 1.07 | 8.21 | 8.21 | 69.11 | -- | -- | -- | -- | 9,784,959.00 | -- | 7.11 | -- | 9.87 | 48.31 | 36.87 | 13.18 | 10.68 | -- | 16.38 | -- | 11.79 | 29.50 | 12.91 | -78.04 | -6.36 | -6.52 | -3.58 |
| Bajaj Healthcare Ltd | 6.91bn | 569.04m | 9.08bn | 1.05k | 15.96 | -- | 11.20 | 1.32 | 20.62 | 20.62 | 250.20 | -- | -- | -- | -- | 6,564,269.00 | -- | 11.38 | -- | 19.70 | 26.47 | 25.65 | 8.24 | 8.64 | -- | 4.44 | -- | -- | 3.49 | 24.14 | -14.11 | 55.61 | 50.96 | -- |
| Suven Life Sciences Ltd | 151.49m | -1.11bn | 10.48bn | 117.00 | -- | -- | -- | 69.17 | -6.67 | -6.67 | 0.9369 | -- | -- | -- | -- | 1,294,812.00 | -- | -9.45 | -- | -10.92 | 76.64 | 65.15 | -735.49 | -19.84 | -- | -360.85 | -- | -- | -12.12 | -53.49 | -69.08 | -- | -8.33 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Motilal Oswal Asset Management Co. Ltd.as of 28 Feb 2023 | 15.00 | 0.00% |
